SHANGHAI, Nov. 12, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, today announced an enhancement to its genomics services. The WuXi Genome Center will provide Chinese researchers who use its gene sequencing services with access to the integrated sequence analysis capabilities of NextCODE Health, a bioinformatics company based in Cambridge, Massachusetts. NextCODE offers the world's only genome analysis system developed at population scale, with uniquely fast and proven capabilities for diagnosing rare diseases and gauging risk of common conditions. NextCODE will work with the WuXi Genome Center to process gene sequencing data of WuXi's customers and produce a report discussing the data's medical implications. This enhancement further enables the research community to leverage the power of next generation sequencing and data analysis for better diagnosis and treatment of disease.
About WuXi PharmaTech
WuXi PharmaTech (NYSE: WX) is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology, and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. Please visit http://www.wuxiapptec.com.
About the WuXi Genome Center
The WuXi Genome Center was established in 2011 to provide sequencing solutions to advance personalized medicine. By integrating with WuXi AppTec's full range of discovery and development services for the biopharmaceutical industry, the WuXi Genome Center provides a complete solution for drug development projects from target discovery and preclinical and clinical development to personalized medicine. The center meets international clinical standards and is the only CLIA-certified clinical genomics lab in China. WuXi has ordered ten Illumina HiSeq X10 sequencing machines and has received six, of which four are operational. In addition to offering sequencing services, WuXi's genomics lab also provides assay development, validation, and testing services.
For further information please contact:
Director of Investor Relations
Associate Director of Corporate Communications
SOURCE WuXi PharmaTech (Cayman) Inc.